Dr. Hoblitzell has served as Senior Vice President, Technical Operations of Assertio since the completion of the Zyla Life Sciences merger in May 2020. Dr. Hoblitzell is responsible for manufacturing, quality, and supply chain, as well as our relationships with contract manufacturers and third-party logistics.
Dr. Hoblitzell has held diverse leadership and executive positions in the pharmaceutical industry spanning research and development, product and process development, manufacturing, and technology transfer for companies such as Zyla, Pfizer, King Pharmaceuticals, Teva, Ivax, Schering-Plough and Johnson and Johnson. Throughout his career, he has proven success in leading cross-functional teams towards successful new product launches and regulatory submissions, as well as operational excellence goals for currently marketed products.
Dr. Hoblitzell holds a bachelor’s degree in Pharmacy and a Doctorate in Pharmaceutics from the University of Rhode Island.
Mr. Patel has served as Senior Vice President, Chief Accounting Officer of Assertio since March 2021. Mr. Patel joined Assertio as Vice President, Controller in July 2019 with responsibility for all accounting policies and practices, internal controls, income taxes and reporting.
Most recently he served in the position of Director, Technical Accounting & Accounting Policy at US Foods, where he oversaw implementation of company-wide accounting policies and helped lead acquisition financial due diligence, with a focus on quality of earnings review and accounting integration activities. Prior to this, he spent 11 years with Ernst & Young holding multiple positions of increasing responsibility in its Assurance practice leading financial statement audits of strategic key clients.
Mr. Patel holds a bachelor’s degree in finance from the University of Illinois, a master’s degree in accounting from the University of Virginia and is a certified public accountant (CPA).
Mr. Schlessinger has served as Vice President, Legal of Assertio since February 2021. Mr. Schlessinger joined Assertio as Senior Corporate Counsel in May 2020 overseeing SEC reporting, corporate governance, due diligence and new business development, capital markets and licensing transactions, litigation, intellectual property, and compliance.
Most recently he served in the position of Corporate Partner for Dentons, LLP where he advised public and privately held clients in mergers and acquisitions, buyouts and recapitalizations, and securities transactions. In this role, he had significant transactional experience representing private equity and other clients in acquisitions and divestitures in regulated industries, with a specialty in healthcare.
Prior to this, he was a Corporate Associate at McDermott Will & Emery LLP, where he focused on pharmaceutical monetization agreements, private equity transactions, leveraged buyouts, mergers and acquisitions, divestitures, and reorganizations.
Mr. Schlessinger holds a bachelor’s degree in mathematics from the Pomona College and a juris doctorate from the University of Illinois.
Mr. Nemmers has served as Head, Investor Relations and Administration of Assertio since February 2021. Mr. Nemmers joined Assertio as Director, Human Resources in February 2019 with responsibility for the Company’s investor relations, communications, succession planning, and leadership development.
Most recently he served in the position of Senior Human Resources Business Partner for Takeda Pharmaceuticals, where he held responsibility for leading the analytical and executional human capital strategy for multiple commercial functions within Takeda’s general medicines business unit.
Prior to this, he worked for Alcon’s surgical business and Abbott Laboratories’ medical optics, vascular, and diabetes care businesses in several progressive leadership roles in mergers and acquisitions, analytics, and strategy development.
Mr. Nemmers holds a bachelor’s degree in communications from Arizona State University. He is a passionate advocate for early childhood education and is a member of the Board of Directors of United Way of Lake County, Illinois, and the Development Board of Kohl Children’s Museum of Greater Chicago.
Mr. Peisert has served as President, Chief Executive Officer, and Director of Assertio since December 2020. Mr. Peisert joined Assertio as Vice President, Business Development in September 2017 and previously held the roles of Senior Vice President, Business Development and Senior Vice President and Chief Financial Officer for the company.
Most recently he served in the position of Vice President of Concordia International Corp.’s US Legacy Pharmaceuticals business where he had full P&L responsibility for the business unit. Prior to this, he was Vice President, Business Development for Concordia and was responsible for executing on the strategic M&A plan. Previously, Mr. Peisert was Director, Finance and Business Development for Marathon Pharmaceuticals, a privately held specialty pharmaceutical company.
Prior to entering the pharmaceutical industry, he was a healthcare Equity Analyst and for Magnetar Capital and a Portfolio Manager for UBS O’Connor and began his career as an Auditor for Price Waterhouse Coopers.
Mr. Peisert holds a bachelor’s degree in business with an emphasis on accounting from the University of Minnesota.
Mr. Schwichtenberg has served as Senior Vice President, Chief Financial Officer of Assertio since March 2021. Mr. Schwichtenberg joined Assertio as Vice President, Finance in April 2018 and has been instrumental in leading Assertio’s financial planning and analysis, financial reporting and controls, gross-to-net planning, risk management, business development due diligence, and modeling.
Most recently he served in the position of Director, Pricing and Planning at AbbVie, where he led the US Commercial Pricing Team of 63 professionals responsible for commercial, institutional and government contracting, government price reporting, financial reporting, and financial planning.
Prior to this, he was a Controller for Radio Flyer, Inc., and Takeda Pharmaceuticals, where he executed numerous enhancements to reporting technology to identify margin opportunities as well as integrated acquisitions across the consumer and pharmaceutical space.
Prior to entering the pharmaceutical industry, he was a senior auditor at Wolf & Company LLP. Mr. Schwichtenberg holds a bachelor’s degree in business administration from Roosevelt University and is a certified public accountant (CPA).